The Microbiome and Prostate Cancer Risk.

Area of Science:

• Microbiome research
• Oncology
• Urology

Background:

• The human microbiome significantly influences metabolism, immunity, and cancer.
• A unique genitourinary (GU) microbiome exists, distinct from other body sites.
• Prostate cancer is increasingly recognized as being influenced by microbial communities.

Purpose of the Study:

• To review current research on the link between the gut and genitourinary microbiome and prostate cancer.
• To explore the role of these microbiomes in prostate cancer development, progression, and treatment.

Main Methods:

• Analysis of formalin-fixed prostate tissue to characterize the prostate microbiota (viral, bacterial, fungal, parasitic).
• Comparison of GU microbiomes in patients with prostate cancer versus benign prostate pathology using urine samples.
• Investigation of gut microbiome associations with prostate cancer and its treatment, including androgen deprivation therapy (ADT).

Main Results:

• Unique microbiome signatures identified in higher Gleason score prostate cancers.
• Evidence of viral genomic insertions into host DNA in prostate cancer tissues.
• Distinct GU microbiomes found in patients with prostate cancer or benign prostate conditions.
• Significant associations between specific gut microbiota and prostate cancer identified.
• Unique microbial signatures observed in patients undergoing oral ADT, with enrichment of androgen synthesis pathways.

Conclusions:

• A unique GU microbiome has been identified.
• Both GU and gut microbiomes are linked to prostate cancer and its treatments.
• Further research is needed to explore the clinical applications of these findings in cancer prevention, diagnosis, and treatment.